Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Anecdotal evidence that cannabis preparations have medical benefits together with the
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …
discovery of the psychotropic plant cannabinoid Δ9-tetrahydrocannabinol (THC) initiated …
[HTML][HTML] 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain
Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key
regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the …
regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the …
Urea derivatives in modern drug discovery and medicinal chemistry
The urea functionality is inherent to numerous bioactive compounds, including a variety of
clinically approved therapies. Urea containing compounds are increasingly used in …
clinically approved therapies. Urea containing compounds are increasingly used in …
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence
Monoacylglycerol lipase (MAGL) regulates endocannabinoid 2-arachidonoylglycerol (2-AG)
and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical …
and eicosanoid signalling. MAGL inhibition provides therapeutic opportunities but clinical …
Identification of ABX-1431, a selective inhibitor of monoacylglycerol lipase and clinical candidate for treatment of neurological disorders
JS Cisar, OD Weber, JR Clapper… - Journal of medicinal …, 2018 - ACS Publications
The serine hydrolase monoacylglycerol lipase (MGLL) converts the endogenous
cannabinoid receptor agonist 2-arachidonoylglycerol (2-AG) and other monoacylglycerols …
cannabinoid receptor agonist 2-arachidonoylglycerol (2-AG) and other monoacylglycerols …
[HTML][HTML] The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases
V Chiurchiù, M van der Stelt, D Centonze… - Progress in …, 2018 - Elsevier
Multiple sclerosis is the most common inflammatory demyelinating disease of the central
nervous system, caused by an autoimmune response against myelin that eventually leads to …
nervous system, caused by an autoimmune response against myelin that eventually leads to …
Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases
C Chen - Pharmacology & therapeutics, 2023 - Elsevier
Endocannabinoids are endogenous lipid signaling mediators that participate in a variety of
physiological and pathological processes. 2-Arachidonoylglycerol (2-AG) is the most …
physiological and pathological processes. 2-Arachidonoylglycerol (2-AG) is the most …
Endocannabinoid-based therapies
The endocannabinoids are lipid-derived messengers that play a diversity of regulatory roles
in mammalian physiology. Dysfunctions in their activity have been implicated in various …
in mammalian physiology. Dysfunctions in their activity have been implicated in various …
Monoacylglycerol lipase (MAGL) as a promising therapeutic target
A Gil-Ordóñez, M Martín-Fontecha… - Biochemical …, 2018 - Elsevier
Monoacylglycerol lipase (MAGL) has been characterized as the main enzyme responsible
for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2 …
for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2 …
[HTML][HTML] The treatment of cognitive, behavioural and motor impairments from brain injury and neurodegenerative diseases through cannabinoid system modulation …
Neurological disorders such as neurodegenerative diseases or traumatic brain injury are
associated with cognitive, motor and behavioural changes that influence the quality of life of …
associated with cognitive, motor and behavioural changes that influence the quality of life of …